PPT-1 Strategies for clinical development of therapeutic vaccines for DR-TB

Mark Hatherill South African Tuberculosis Vaccine Initiative SATVI University of Cape Town South Africa 2 The case for a therapeutic vaccine for DRTB What could a therapeutic vaccine do What could we do with a therapeutic vaccine. Vaccine Program. VRBPAC Meeting. . Robin Robinson, Ph.D. . Director, BARDA. Deputy Assistant Secretary, ASPR. February 29, 2012. 1. Pre-2003 Pandemic Influenza . Vaccine Goal & Strategy . Egg-based Vaccines. Tanapat. . Palaga. , PhD. Department of Microbiology. Faculty of Science. Chulalongkorn. University. NVI: 11/07/12. TB Vaccines. The Stop TB Partnership (WHO) announced the goal of eliminating tuberculosis by the year 2050 (one new TB case per million) . Scientific Director . Advanced . BioScience. Laboratories. Maryland, USA. 1. Vaccines work by mimicking disease agents and stimulating the immune system to build up defenses against . them. Vaccine design and development. Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI 1 2 Summary of the AIDS epidemic 2016 Necessity to go beyond cART Since the introduction of ART 20 years ago, CUMENT1March 2021WORKING DOCUMENT2Executive Summary Since 2017CEPI has established itself as an integralpart of the global health security systemThe responseto COVID-19 C CEPI provided early ig across the product lifespan. TRUSTED to ensure the SAFETY and EFFICACY of all therapeutic products. FLEXIBLE and RISK APPROPRIATE with enabling legislation framework to ensure therapeutic products are ACCESSIBLE . Fox Subacute. What is mRNA. ?. An RNA vaccine or mRNA vaccine is a type of vaccine that uses a man-made copy of a natural chemical called messenger RNA to produce an immune response. . Unlike most vaccines, which use a modified virus or viral protein to elicit an immune response, the Pfizer-. M. uted. Unmuted. Please ensure that your line is not generating background noise. We are recording this webinar; you will be placed on mute by default. Please remain on mute if you are not speaking to maintain the quality of the recording. at HHS. Armen Donabedian. ASPR/BARDA. 4. th. Annual CLS Symposium. Auburn University. March 31, 2017. https://wwwnc.cdc.gov/travel/files/zika-areas-of-risk.pdf. 2. Rick Bright, . Ph.D. BS in Biology . - on COVID - 19 Vaccines for P eople with S plenectomy or F unctional A splenia This guidance is intended for health - care providers . It is based on known evidence as of March 1 , 2022 . Bac Richard A. . Koup. , MD. Acting Director. Vaccine Research Center. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Bethesda, Maryland. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Institute for Glycomics, Griffith University. Malaria Vaccines 101. Why don’t we have a malaria vaccine?. -Complexity of the parasite. Which Plasmodium species should a vaccine target?. -There are 6 main species of malaria parasite that infect humans: . onfidential.  Presentation. Overview. 2. Acuitas. works with partners across different therapeutic areas & indications.  to accelerate entry into the clinic.. Foundations . & . NGOs. Leading . Educational Webinar. September 9, 2011. Ellen G. Feigal, M.D.. Vice President, Research and Development. California Institute for Regenerative Medicine. Webinar objective is to help address your questions as you prepare your application.